Zurcher Kantonalbank (Zurich Cantonalbank) Cellectis S.A. Transaction History

Zurcher Kantonalbank (Zurich Cantonalbank)

$39 Billion
Q2 2025

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 Apr 21, 2022	SELL	$3.45 - $8.77 $6,668 - $16,952	-1,933 Closed	0 $0
Q4 2021 Feb 01, 2022	SELL	$8.01 - $12.84 $1,610 - $2,580	-201 Reduced 9.42%	1,933 $16,000
Q3 2021 Nov 15, 2021	BUY	$11.94 - $16.09 $35 - $48	3 Added 0.14%	2,134 $27,000
Q2 2021 Jul 30, 2021	BUY	$14.36 - $20.93 $2,814 - $4,102	196 Added 10.13%	2,131 $33,000
Q1 2021 May 03, 2021	BUY	$18.19 - $33.25 $35,197 - $64,338	1,935 New	1,935 $39,000

Others Institutions Holding CLLS

# of Institutions

Shares Held

13.2M

Call Options Held

Put Options Held

Long Focus Capital Management, LLC San Juan, PR

4.72M
Shares

$16.6 Million
0.33% of portfolio
B Group, Inc. Dallas, TX

3.26M
Shares

$11.5 Million
3.82% of portfolio
Ubs Asset Management Americas Inc Chicago, IL

3.18M
Shares

$11.2 Million
0.0% of portfolio
Credit Suisse Ag Zurich, V8

1.44M
Shares

$5.06 Million
0.0% of portfolio
Macquarie Group LTD Australia, C3

227K
Shares

$798,600
0.0% of portfolio

View Full List

About Cellectis S.A.

Ticker CLLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,510,800
Market Cap $160M
Description
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...

More about CLLS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Zurcher Kantonalbank (Zurich Cantonalbank), based on Form 13F filings with the SEC.

News

Stay updated on Zurcher Kantonalbank (Zurich Cantonalbank) with notifications on news.

Account